Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Journal of the American College of Cardiology
|
December 26, 2012
Remnant cholesterol as a causal risk factor for ischemic heart disease
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, et al.
European Journal of Epidemiology
|
September 5, 2021
Low and high pancreatic amylase is associated with pancreatic cancer and chronic pancreatitis
Signe E J Hansen, Anne Langsted, Anette Varbo, et al.
Clinical Chemistry
|
February 19, 2016
Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease
Anne-Marie K Jepsen, Anne Langsted, Anette Varbo, et al.
Journal of the American College of Cardiology
|
January 11, 2023
Elevated LDL Triglycerides and Atherosclerotic Risk
Mie Balling, Shoaib Afzal, George Davey Smith, et al.
Atherosclerosis
|
August 21, 2025
Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study
Mie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Journal of Clinical Lipidology
|
January 30, 2026
VLDL cholesterol and ASCVD risk: A population-based study
Mie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Clinical Obesity
|
November 25, 2024
Healthcare utilization associated with obesity management in Ontario, Canada
Sean Wharton, Adel Belloum, Maria Luckevich, et al.
The Lancet. Diabetes & Endocrinology
|
August 1, 2024
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Barbara M McGowan, Jens M Bruun, Matt Capehorn, et al.
Diabetes Care
|
June 20, 2022
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
Leigh Perreault, Melanie Davies, Juan P Frias, et al.
American Journal of Human Genetics
|
May 30, 2017
Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits
Ioanna Tachmazidou, Dániel Süveges, Josine L Min, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Journal of the American College of Cardiology
|
December 26, 2012
Remnant cholesterol as a causal risk factor for ischemic heart disease
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, et al.
European Journal of Epidemiology
|
September 5, 2021
Low and high pancreatic amylase is associated with pancreatic cancer and chronic pancreatitis
Signe E J Hansen, Anne Langsted, Anette Varbo, et al.
Clinical Chemistry
|
February 19, 2016
Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease
Anne-Marie K Jepsen, Anne Langsted, Anette Varbo, et al.
Journal of the American College of Cardiology
|
January 11, 2023
Elevated LDL Triglycerides and Atherosclerotic Risk
Mie Balling, Shoaib Afzal, George Davey Smith, et al.
Atherosclerosis
|
August 21, 2025
Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study
Mie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Journal of Clinical Lipidology
|
January 30, 2026
VLDL cholesterol and ASCVD risk: A population-based study
Mie Balling, Otto Grøn Roepstorff, Thomas Alexander Gerds, et al.
Clinical Obesity
|
November 25, 2024
Healthcare utilization associated with obesity management in Ontario, Canada
Sean Wharton, Adel Belloum, Maria Luckevich, et al.
The Lancet. Diabetes & Endocrinology
|
August 1, 2024
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Barbara M McGowan, Jens M Bruun, Matt Capehorn, et al.
Diabetes Care
|
June 20, 2022
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
Leigh Perreault, Melanie Davies, Juan P Frias, et al.
American Journal of Human Genetics
|
May 30, 2017
Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits
Ioanna Tachmazidou, Dániel Süveges, Josine L Min, et al.
Page
of 6